Previous Close | 14.93 |
Open | 15.09 |
Bid | 14.41 x 1300 |
Ask | 15.39 x 1200 |
Day's Range | 14.58 - 15.36 |
52 Week Range | 12.90 - 76.22 |
Volume | |
Avg. Volume | 628,132 |
Market Cap | 2.735B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.87 |
Earnings Date | Nov 18, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.85 |
TĂśBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Insiders often own a large...
* Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer * Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigensTĂśBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicine